Details of Disease | DrugMAP

General Information of Disease (ID: DIS63VJD)

Disease Name	Autoimmune pulmonary alveolar proteinosis
Synonyms	acquired pulmonary alveolar proteinosis; pulmonary alveolar proteinosis, acquired; pulmonary alveolar proteinosis autoimmune; PAP; pulmonary alveolar proteinosis, autoimmune; pulmonary alveolar lipoproteinosis acquired; pulmonary alveolar proteinosis acquired; Pap, acquired; PAP acquired; pulmonary alveolar lipoproteinosis, acquired; APAP; autoimmune PAP; iPAP; idiopathic pulmonary alveolar proteinosis; idiopathic PAP; Pulmonary Alveolar Proteinosis
Disease Class	CB04: Infancy/childhood primary interstitial lung disease
Definition	Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of a lipoproteinaceous substance in the distal air spaces which positively stains with periodic acid-Schiff (PAS).
Disease Hierarchy	DISGC6JB: Pulmonary alveolar proteinosis DISORMTM: Autoimmune disease DIS63VJD: Autoimmune pulmonary alveolar proteinosis
ICD Code	ICD-11 ICD-11: CB04.31
Disease Identifiers	MONDO ID MONDO_0012579 MESH ID C567049 UMLS CUI C1970472 OMIM ID 610910 MedGen ID 410079 Orphanet ID 747 SNOMED CT ID 707443007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Molgramostim	DM2TNJ1	Phase 3	NA	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	ClinicalTrials.gov (NCT04544293) Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (IMPALA-2). U.S. National Institutes of Health.